- Home
- DLB vs JAZZ Comparison
DLB vs JAZZ Comparison
Compare DLB & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLB
- JAZZ
- Stock Information
- Founded
- DLB 1965
- JAZZ 2003
- Country
- DLB United States
- JAZZ Ireland
- Employees
- DLB N/A
- JAZZ N/A
- Industry
- DLB Multi-Sector Companies
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- DLB Miscellaneous
- JAZZ Health Care
- Exchange
- DLB Nasdaq
- JAZZ Nasdaq
- Market Cap
- DLB 7.4B
- JAZZ 8.2B
- IPO Year
- DLB 2005
- JAZZ 2007
- Fundamental
- Price
- DLB $66.55
- JAZZ $136.93
- Analyst Decision
- DLB Strong Buy
- JAZZ Strong Buy
- Analyst Count
- DLB 5
- JAZZ 14
- Target Price
- DLB $96.60
- JAZZ $179.43
- AVG Volume (30 Days)
- DLB 462.3K
- JAZZ 649.4K
- Earning Date
- DLB 11-18-2025
- JAZZ 11-05-2025
- Dividend Yield
- DLB 1.98%
- JAZZ N/A
- EPS Growth
- DLB 24.38
- JAZZ N/A
- EPS
- DLB 2.71
- JAZZ N/A
- Revenue
- DLB $1,346,912,000.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- DLB $6.77
- JAZZ $5.75
- Revenue Next Year
- DLB $4.41
- JAZZ $6.09
- P/E Ratio
- DLB $24.56
- JAZZ N/A
- Revenue Growth
- DLB 6.94
- JAZZ 4.52
- 52 Week Low
- DLB $66.52
- JAZZ $95.49
- 52 Week High
- DLB $89.66
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- DLB 33.26
- JAZZ 55.63
- Support Level
- DLB $66.96
- JAZZ $136.38
- Resistance Level
- DLB $68.15
- JAZZ $140.00
- Average True Range (ATR)
- DLB 1.31
- JAZZ 3.01
- MACD
- DLB -0.16
- JAZZ -0.32
- Stochastic Oscillator
- DLB 0.64
- JAZZ 59.54
About DLB Dolby Laboratories
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company designs and manufactures audio, imaging, accessibility, and other hardware and software solutions for the cinema, with occasional applications in the television, broadcast, and live entertainment industries. The company operates in the United States and internationally.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.